Soligenix
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Soligenix sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Soligenix: 10 sponsored US clinical trials, 1 recruiting.
Soligenix sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 4 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, with 1 trials.
Top-decile sponsor footprint
Soligenix ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
10 total, page 1 of 1
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
NCT06470451
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
NCT06149247
Topical SGX302 for Mild-to-Moderate Psoriasis
NCT05442190
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
NCT05380635
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
NCT03237325
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
NCT02448381
A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
NCT02013050
Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)
NCT01925950
A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer
NCT01073384
Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
NCT00926575
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 4 |
What is open in the Soligenix pipeline
1 recruiting of 10 indexed (10% open); 7 completed (70%).
Phase mix: 4 late (III/IV) vs 6 early (I/II) (balanced across stages).
Top condition: Squamous Cell Carcinoma of the Oral Cavity and Oropharynx (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Soligenix: open-pipeline peers nationwide
Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Soligenix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 trials (± recruiting share)
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Abiomed · 10% recruiting · 20 trials
- Aimmune Therapeutics · 10% recruiting · 10 trials
- Altria Client Services · 10% recruiting · 10 trials
- Alzheimer's Disease Cooperative Study (ADCS) · 10% recruiting · 10 trials
Related
What to do with this Soligenix page
10 registered trials is a research-attention snapshot, not an endorsement of Soligenix or any single study.
- 1 of Soligenix's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Squamous Cell Carcinoma of the Oral Cavity and Oropharynx is the condition Soligenix studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Squamous Cell Carcinoma of the Oral Cavity and Oropharynx trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Soligenix pipeline card: 10 registered trials from official public datasets.Report a data error.